These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34389606)

  • 1. Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry".
    van Vollenhoven RF; Tas SW; Nurmohamed MT
    Ann Rheum Dis; 2023 Aug; 82(8):e177. PubMed ID: 34389606
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks
    Gremese E; Ferraccioli G
    Ann Rheum Dis; 2023 Jul; 82(7):e157. PubMed ID: 34426399
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks
    Wallace ZS; Sparks JA; Robinson PC; Machado PM; Yazdany J
    Ann Rheum Dis; 2023 Jul; 82(7):e158. PubMed ID: 34426400
    [No Abstract]   [Full Text] [Related]  

  • 4. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
    Sparks JA; Wallace ZS; Seet AM; Gianfrancesco MA; Izadi Z; Hyrich KL; Strangfeld A; Gossec L; Carmona L; Mateus EF; Lawson-Tovey S; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Pons-Estel GJ; Isnardi CA; Berbotto GA; Hsu TY; D'Silva KM; Patel NJ; Kearsley-Fleet L; Schäfer M; Ribeiro SLE; Al Emadi S; Tidblad L; Scirè CA; Raffeiner B; Thomas T; Flipo RM; Avouac J; Seror R; Bernardes M; Cunha MM; Hasseli R; Schulze-Koops H; Müller-Ladner U; Specker C; Souza VA; Mota LMHD; Gomides APM; Dieudé P; Nikiphorou E; Kronzer VL; Singh N; Ugarte-Gil MF; Wallace B; Akpabio A; Thomas R; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Yazdany J;
    Ann Rheum Dis; 2021 Sep; 80(9):1137-1146. PubMed ID: 34049860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by van Vollenhoven
    Sparks JA; Wallace ZS; Seet AM; Robinson PC; Machado PM; Yazdany J
    Ann Rheum Dis; 2023 Aug; 82(8):e178. PubMed ID: 34389604
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
    Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco
    Giollo A; Bertoldo E; Adami G; Cybulski AJ; Fassio A; Orsolini G; Idolazzi L; Gatti D; Viapiana O; Rossini M
    Ann Rheum Dis; 2022 Nov; 81(11):e222. PubMed ID: 32895237
    [No Abstract]   [Full Text] [Related]  

  • 8. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).
    Rath E; Bonelli M; Duftner C; Gruber J; Mandl P; Moazedi-Furst F; Pieringer H; Puchner R; Flick H; Salzer HJF; Weiss G; Winkler S; Skvara H; Moschen A; Hofer H; Feurstein J; Sautner J
    Wien Klin Wochenschr; 2022 Nov; 134(21-22):751-765. PubMed ID: 36036323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
    Bathon JM; Cohen SB
    Arthritis Rheum; 2008 Jun; 59(6):757-9. PubMed ID: 18512712
    [No Abstract]   [Full Text] [Related]  

  • 12. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
    Singh JA; Furst DE; Bharat A; Curtis JR; Kavanaugh AF; Kremer JM; Moreland LW; O'Dell J; Winthrop KL; Beukelman T; Bridges SL; Chatham WW; Paulus HE; Suarez-Almazor M; Bombardier C; Dougados M; Khanna D; King CM; Leong AL; Matteson EL; Schousboe JT; Moynihan E; Kolba KS; Jain A; Volkmann ER; Agrawal H; Bae S; Mudano AS; Patkar NM; Saag KG
    Arthritis Care Res (Hoboken); 2012 May; 64(5):625-39. PubMed ID: 22473917
    [No Abstract]   [Full Text] [Related]  

  • 13. Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Graudal N; Jürgens G
    Arthritis Care Res (Hoboken); 2013 May; 65(5):832. PubMed ID: 23097263
    [No Abstract]   [Full Text] [Related]  

  • 14. Design characteristics of the Corrona Japan rheumatoid arthritis registry.
    Yamanaka H; Kishimoto M; Pappas DA; Greenberg JD; Kremer JM; Tanaka Y
    Mod Rheumatol; 2018 Jan; 28(1):95-100. PubMed ID: 28448195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
    Saag KG; Teng GG; Patkar NM; Anuntiyo J; Finney C; Curtis JR; Paulus HE; Mudano A; Pisu M; Elkins-Melton M; Outman R; Allison JJ; Suarez Almazor M; Bridges SL; Chatham WW; Hochberg M; MacLean C; Mikuls T; Moreland LW; O'Dell J; Turkiewicz AM; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):762-84. PubMed ID: 18512708
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.
    Pombo-Suarez M; Gomez-Reino J
    Pharmacol Res; 2019 Oct; 148():104410. PubMed ID: 31461667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.
    Rosenbaum JT; Weisman MH; Shafer C; Aslanyan E; Howard RA; Ogle K; Hamilton H; Reveille JD; Winthrop KL; Choi D
    Ann Rheum Dis; 2023 Jun; 82(6):e138. PubMed ID: 33985940
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.
    Emery P; Sebba A; Huizinga TW
    Ann Rheum Dis; 2013 Dec; 72(12):1897-904. PubMed ID: 23918035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Conn DL
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1622-3; author reply 1623-4. PubMed ID: 23024030
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.